...
首页> 外文期刊>Current Organic Synthesis >Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
【24h】

Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids

机译:子宫肌瘤药理治疗中选择性孕激素受体调节剂(Ulipristal醋酸盐)的预测因素

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Selective progesterone receptor modulator ulipristal acetate (UPA) is a drug used in management of symptomatic myomas. It was observed that the response to UPA treatment in uterine myomas varied amongst patients. An attempt was thus made at establishing predictive factors conducive to better reaction to treatment with UPA. The aim of this study was to assess the efficacy of UPA treatment in women with myomas, depending on pretreatment myomas' volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Materials and methods: The study included patients with one to four myomas. The UPA treatment was a preparation stage for surgical treatment in all patients. The study group was divided into the subgroups according to pretreatment myomas' volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Results: A better effect of reduction in size of myomas after UPA treatment was noted when pretreatment myomas' volume was lower than 30 cm(3). A significant reduction in fibroids' size was observed after UPA therapy independently of the number of myomas and age of patients. A good response after the UPA therapy was observed when pretreatment estradiol concentration was below 50 pg/mL and when uterine artery resistance index (RI) was above 0.8. Conclusions: Our research demonstrates that treatment with ulipristal acetate is an efficient method in preoperative preparation of patients with uterine fibroids. The most important factor of positive response to UPA therapy is myoma volume. The number of myomas and patient's age do not interfere with effects of UPA therapy. Pretreatment estradiol concentration is significant, yet secondary for the effects of therapy. The UPA therapy has no impact on blood flow in the uterine arteries and no adverse influence on estradiol concentrations.
机译:背景:选择性孕激素受体调节剂ulipristal醋酸盐(UPA)是一种用于管理症状肌瘤的药物。观察到,在子宫肌瘤中对UPA治疗的反应在患者中变化。因此,在建立有利于对UPA治疗的更好反应的预测因素时,尝试。本研究的目的是评估upa治疗在妇女的疗效,根据预处理肌瘤的体积,患有患者年龄,患者年龄,女性雌激素状态以及子宫动脉的预处理血流。材料和方法:该研究包括一到四名Myomas的患者。 UPA治疗是所有患者手术治疗的制备阶段。研究组根据预处理Myomas的体积,眼部次数,患者年龄,女性的雌激素状态和子宫动脉预处理的血流等亚组。结果:在预处理Myomas的体积低于30cm(3)时,注意到upa治疗后肌瘤尺寸的更好效果。在upa治疗之后观察到肌瘤大小的显着降低,独立于患者的眼部和年龄的数量。当预处理雌二醇浓度低于50pg / mL时,观察到uPA治疗后的良好反应,并且当子宫动脉抗性指数(RI)高于0.8时。结论:我们的研究表明,尿醋酸盐的治疗是术前制剂尿素肌瘤术前的一种有效方法。对UPA治疗的积极反应的最重要因素是肌瘤体积。 Myomas和患者年龄的数量不会干扰UPA治疗的影响。预处理雌二醇浓度是显着的,患有治疗的影响是显着的,但继发性。 UPA治疗对子宫动脉血流没有影响,对雌二醇浓度没有不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号